Search Results - (Author, Cooperation:P. K. Marcom)
-
1M. J. Ellis ; L. Ding ; D. Shen ; J. Luo ; V. J. Suman ; J. W. Wallis ; B. A. Van Tine ; J. Hoog ; R. J. Goiffon ; T. C. Goldstein ; S. Ng ; L. Lin ; R. Crowder ; J. Snider ; K. Ballman ; J. Weber ; K. Chen ; D. C. Koboldt ; C. Kandoth ; W. S. Schierding ; J. F. McMichael ; C. A. Miller ; C. Lu ; C. C. Harris ; M. D. McLellan ; M. C. Wendl ; K. DeSchryver ; D. C. Allred ; L. Esserman ; G. Unzeitig ; J. Margenthaler ; G. V. Babiera ; P. K. Marcom ; J. M. Guenther ; M. Leitch ; K. Hunt ; J. Olson ; Y. Tao ; C. A. Maher ; L. L. Fulton ; R. S. Fulton ; M. Harrison ; B. Oberkfell ; F. Du ; R. Demeter ; T. L. Vickery ; A. Elhammali ; H. Piwnica-Worms ; S. McDonald ; M. Watson ; D. J. Dooling ; D. Ota ; L. W. Chang ; R. Bose ; T. J. Ley ; D. Piwnica-Worms ; J. M. Stuart ; R. K. Wilson ; E. R. Mardis
Nature Publishing Group (NPG)
Published 2012Staff ViewPublication Date: 2012-06-23Publisher: Nature Publishing Group (NPG)Print ISSN: 0028-0836Electronic ISSN: 1476-4687Topics: BiologyChemistry and PharmacologyMedicineNatural Sciences in GeneralPhysicsKeywords: Androstadienes/pharmacology/therapeutic use ; Antineoplastic Agents/pharmacology/therapeutic use ; Aromatase/*metabolism ; Aromatase Inhibitors/*therapeutic use ; Breast Neoplasms/*drug therapy/*genetics/metabolism/pathology ; DNA Repair ; Exome/genetics ; Exons/genetics ; Female ; Genetic Variation/genetics ; Genome, Human/*genetics ; Humans ; MAP Kinase Kinase 4/genetics ; MAP Kinase Kinase Kinase 1/genetics ; Mutation/genetics ; Nitriles/pharmacology/therapeutic use ; Receptors, Estrogen/metabolism ; Treatment Outcome ; Triazoles/pharmacology/therapeutic usePublished by: -
2Burstein, H. J. ; Ramirez, M. J. ; Petros, W. P. ; Clarke, K. D. ; Warmuth, M. A. ; Marcom, P. K. ; Matulonis, U. A. ; Parker, L. M. ; Harris, L. N. ; Winer, E. P.
Springer
Published 1999Staff ViewISSN: 1569-8041Keywords: Doxil ; metastatic breast cancer ; phase I ; vinorelbineSource: Springer Online Journal Archives 1860-2000Topics: MedicineNotes: Abstract Background: Vinorelbine and Doxil (liposomal doxorubicin) are active chemotherapeutic agents in metastatic breast cancer. A phase I study was designed to evaluate combination therapy. Patients and methods: Thirty women with metastatic breast cancer were enrolled. Dose-limiting toxicity was determined through a dose escalation scheme, and defined for the first treatment cycle, only. Pharmacokinetic studies were performed during the first cycle of treatment. Results: In the first cohort of Doxil 30 mg/m2 day 1 and vinorelbine 25 mg/m2 days 1 and 8, patients experienced severe neutropenia. Vinorelbine administration was changed thereafter to days 1 and 15 of each cycle. Dose limiting toxicity was observed at Doxil 50 mg/m2 and vinorelbine 25 mg/m2. Doxil 40 mg/m2 and vinorelbine 30 mg/m2 was defined as the maximally tolerated dose. Few toxicities (principally neutropenia) were seen at this dose level, with the notable absence of significant nausea, vomiting, or alopecia. Though 63% of patients had received prior anthracycline-based chemotherapy, only one patient developed grade 2 cardiac toxicity. Pharmacokinetic studies revealed prolonged exposure to high doxorubicin concentrations for several days following Doxil administration. Conclusions: Combination chemotherapy with Doxil and vinorelbine affords treatment with two active drugs in women with metastatic breast cancer, and appears to have a favorable toxicity profile. A schedule of Doxil 40 mg/m2 day 1 and vinorelbine 30 mg/m2 days 1 and 15 given every 28 days is recommended for phase II studies.Type of Medium: Electronic ResourceURL: -
3Noebels, J. L. ; Marcom, P. K. ; Jalilian-Tehrani, M. H.
[s.l.] : Nature Publishing Group
Published 1991Staff ViewISSN: 1476-4687Source: Nature Archives 1869 - 2009Topics: BiologyChemistry and PharmacologyMedicineNatural Sciences in GeneralPhysicsNotes: [Auszug] We prepared autoradiograms of adult shi /shi and +/+ brain sections and performed regional binding assays with tritiated saxitoxin, which binds externally to the membrane-bound9 but not to the free intracellular form10 of the sodium channel a subunit, the peptide requisite for ion conduction11. ...Type of Medium: Electronic ResourceURL: